Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Seralutinib · GB-002, PK-10571

Small molecule · developed by GB002, Inc., a wholly owned subsidiary of Gossamer Bio

Phase 3 Most advanced trial

GOSS Developer

3 Registered trials

What is Seralutinib?

Seralutinib is an investigational small-molecule drug studied in Pulmonary Arterial Hypertension.

At a glance

Also known as: GB-002, PK-10571
Drug type: Small molecule
Therapy area: Respiratory
Developer: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. (GOSS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 3P63ZTE3OY

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06274801	Phase 3	Pulmonary Arterial Hypertension	Recruiting	GOSS
NCT04816604	Phase 2	Pulmonary Arterial Hypertension	Terminated	GOSS
NCT03926793	Phase 1	Pulmonary Arterial Hypertension	Completed	GOSS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Arterial Hypertension

More from GB002, Inc., a wholly owned subsidiary of Gossamer Bio

GB001 Phase 2 GB004 Phase 1 GB1275 Phase 1 GB5121 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GOSS page.

Follow GOSS, the company behind Seralutinib

See GOSS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GOSS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z